Novel anticoagulants: Bleeding risk and management strategies

Current Opinion in Gastroenterology

Volumn 29, Issue 6, 2013, Pages 676-683

  Abraham, Neena S ^a   Castillo, Diana L ^b  

^a MAYO CLINIC   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute gastrointestinal hemorrhage; apixaban; dabigatran; endoscopy

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 7; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; PROTHROMBIN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG EXCRETION; DRUG HALF LIFE; DRUG MONITORING; ENDOSCOPY; FLUID RESUSCITATION; GASTROINTESTINAL HEMORRHAGE; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; MEDICAL LITERATURE; PROFESSIONAL KNOWLEDGE; REVIEW; THROMBOEMBOLISM; THROMBOSIS; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BIOMEDICAL RESEARCH; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL HEMORRHAGE; HUMANS; RISK ASSESSMENT; WARFARIN;

EID: 84886101115     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328365d415     Document Type: Review

References (27)

1. Abraham NS. Novel oral anticoagulants and gastrointestinal bleeding: a case & for cardiogastroenterology. Clin Gastroenterol Hepatol 2013; 11:324-328.
2. Kirley K, Qato DM, Kornfield R, et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012; 5:615-621.
3. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:1916-1926.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
5. Oldgren J, Budaj A, Granger CB, et al., RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781-2789.
6. Chung N, Jeon HK, Lien LM, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with nonvalvular atrial fibrillation. Thromb Haemost 2011; 105:535-544.
7. Granger CB, Alexander JH, McMurray JJ, et al., ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
8. APPRAISE Steering Committee and Investigators. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119:2877-2885.
9. Alexander JH, Lopes RD, James S, et al., APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365:699-708.
10. Patel MR, Mahaffey KW, Garg J, et al., and the ROCKET AF Steering Committee for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
11. Mega JL, Braunwald E, Wiviott SD, et al., the ATLAS ACS. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9-19.
12. Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110:453-460.
13. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013; 145:105-112.
14. Komocsi A, Vorobcsuk A, Kehl D, Aradi D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:1537-1545.
15. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012; 126:1185-1193.
16. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138:1093-1100.
17. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57:173-180.
18. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107:584-589.
19. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-2870. (Pubitemid 32537350)
20. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137:263-272.
21. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin-what's the risk? Aliment Pharmacol Ther 2006; 24:897-908. (Pubitemid 44326371)
22. De Caterina R, Husted S, Wallentin L, et al., Coordinating Committee. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012; 59:1413-1425.
23. ASGE Standards of Practice Committee. Anderson MA, Ben-Menachem T, Gan SI, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70:1060-1070.
24. Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management andapproach to bleeding in patients taking dabigatran. Circulation 2012; 126:2428-2432.
25. Becker RC, Scheiman J, Dauerman HL, et al., American College of Cardiology and the American College of Gastroenterology. Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. Am J Gastroenterol 2009; 104:2903-2917.
26. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation ofcoagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116-1127.
27. Pare G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013; 127:1404-1412.